Author:
Bennett A. N.,Peterson P.,Zain A.,Grumley J.,Panayi G.,Kirkham B.
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Reference11 articles.
1. Weinblatt ME, Keystone EC, Furst DE et al. Adalimumab, a fully human anti-rheumatoid arthritis in patients taking concomitant methotrexate. Arthritis Rheum2003;48:35–45.
2. Furst DE, Schiff MH, Fleischmann RM et al. Adalimumab, a fully human anti-tumour necrosis factor-α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (safety trial of adalimumab in rheumatoid arthritis). J Rheumatol2003;30: 2563–71.
3. Van de Putte LBA, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis2004; 63:508–16.
4. Ang HTS, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with other tumour necrosis factor-α antagonists in patients with rheumatoid arthritis? J Rheumatol2003;30:2315–8.
5. van Vollenhaven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis2003;62:1195–8.